DDInter41 DDInter350
Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Alemtuzumab was approved by the FDA in 2001. It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL). The dose of alemtuzumab used for B-CLL is
A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Melphalan
Melphalan {u} (Compound) resembles {v} (Compound) Chlorambucil
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ibuprofen
Ibuprofen {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} (Compound) resembles {v} (Compound) Chlorambucil
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Melphalan
Melphalan {u} (Compound) treats {v} (Disease) ovarian cancer
ovarian cancer {u} (Disease) is treated by {v} (Compound) Chlorambucil
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Melphalan
Melphalan {u} (Compound) resembles {v} (Compound) Chlorambucil
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ibuprofen
Ibuprofen {u} (Compound) binds {v} (Gene) SLCO1A2
SLCO1A2 {u} (Gene) is bound by {v} (Compound) Chlorambucil
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ibuprofen
Ibuprofen {u} (Compound) causes {v} (Side Effect) Leukopenia
Leukopenia {u} (Side Effect) is caused by {v} (Compound) Chlorambucil
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Efalizumab
Efalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Melphalan
Melphalan {u} (Compound) resembles {v} (Compound) Chlorambucil
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} (Compound) downregulates {v} (Gene) DDB2
DDB2 {u} (Gene) is upregulated by {v} (Compound) Chlorambucil
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Melphalan
Melphalan {u} (Compound) upregulates {v} (Gene) DDB2
DDB2 {u} (Gene) is upregulated by {v} (Compound) Chlorambucil
Alemtuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Radium Ra 223 dichloride
Radium Ra 223 dichloride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Melphalan
Melphalan {u} (Compound) resembles {v} (Compound) Chlorambucil
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan (Compound) resembles Chlorambucil (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen (Compound) resembles Melphalan (Compound) and Melphalan (Compound) resembles Chlorambucil (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan (Compound) treats ovarian cancer (Disease) and ovarian cancer (Disease) is treated by Chlorambucil (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Melphalan and Melphalan (Compound) resembles Chlorambucil (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen (Compound) binds SLCO1A2 (Gene) and SLCO1A2 (Gene) is bound by Chlorambucil (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Chlorambucil (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan (Compound) resembles Chlorambucil (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib (Compound) downregulates DDB2 (Gene) and DDB2 (Gene) is upregulated by Chlorambucil (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan (Compound) upregulates DDB2 (Gene) and DDB2 (Gene) is upregulated by Chlorambucil (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride and Radium Ra 223 dichloride may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan (Compound) resembles Chlorambucil (Compound)